Plus   Neg

Moderna Regains Rights To Respiratory Syncytial Virus Vaccine From Merck - Quick Facts

Moderna, Inc., (MRNA) said it has regained all rights to the respiratory syncytial virus vaccine (mRNA-1172) from Merck, including rights to develop RSV vaccines for adult populations. Merck will complete the phase 1 study and transition the program to Moderna.

Moderna also announced the initiation of dosing in the phase 1 study of its solely owned RSV vaccine candidate (mRNA-1345). This phase 1 study includes initial dosing in adults, followed by age de-escalation into children.

Moderna and Merck will continue their ongoing collaboration in cancer vaccines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
American Airlines announced the launch of Flagship Cellars, its home delivery service for premium wines usually available onboard. The airline's move is said to be due to the excess wine it has amid the weakness in air travel demand following the coronavirus pandemic crisis. The company expects the new at-home wine program to generate about $40,000 to $50,000 in sales during the first quarter. Intel Corp. is planning to manufacture majority of its 2023 products internally, while it may outsource some, according to the incoming Chief Executive Officer Pat Gelsinger. At the fourth-quarter earnings webcast, while talking about 7nm program development, Gelsinger said, "I am confident that the majority of our 2023 products will be manufactured internally...." American Airlines has extended its offer to waive change fees for customers who purchase tickets for travel, until March 31 in response to lower travel demand due to the coronavirus pandemic. This means that travelers are provided additional flexibility by not asking them to pay penalties for changing the origin and destination cities.
Follow RTT